Newsfeeds - Spark Newswire

2 minute read

General
Health Care
News
Penny Stocks
Small Cap

CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS

Today, 3:01 PM

Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In addition, NASH is expected to become the leading indicator for liver transplants in men.

CANF

2 minute read

Uncategorized

CAN-FITE BIOPHARMA ANNOUNCES ADVANCEMENT OF CLINICAL STUDIES AND NEW EUROPEAN LICENSING AGREEMENTS

By Mark Gilman

Today, 3:01 PM

by Mark Gilman Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), an Israeli-based biotechnology company advancing a pipeline of proprietary small-molecule drugs that address inflammatory, cancer and liver diseases, continues to expand its reach in the treatment of cancer, liver and inflammatory disease.

CANF

Latest news

CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS

CAN-FITE BIOPHARMA ANNOUNCES ADVANCEMENT OF CLINICAL STUDIES AND NEW EUROPEAN LICENSING AGREEMENTS